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Abstract
Background: The oxidation of fatty acids in mitochondria plays an important role in energy metabolism and
genetic disorders of this pathway may cause metabolic diseases. Enzyme deficiencies can block the metabolism at
defined reactions in the mitochondrion and lead to accumulation of specific substrates causing severe clinical
manifestations. Ten of the disorders directly affecting mitochondrial fatty acid oxidation have been well-defined,
implicating episodic hypoketotic hypoglycemia provoked by catabolic stress, multiple organ failure, muscle
weakness, or hypertrophic cardiomyopathy. Additionally, syndromes of severe maternal illness (HELLP syndrome
and AFLP) have been associated with pregnancies carrying a fetus affected by fatty acid oxidation deficiencies.
However, little is known about fatty acids kinetics, especially during fasting or exercise when the demand for fatty
acid oxidation is increased (catabolic stress).
Results:  A computational kinetic network of 64 reactions with 91 compounds and 301 parameters was
constructed to study dynamic properties of mitochondrial fatty acid β-oxidation. Various deficiencies of acyl-CoA
dehydrogenase were simulated and verified with measured concentrations of indicative metabolites of screened
newborns in Middle Europe and South Australia. The simulated accumulation of specific acyl-CoAs according to
the investigated enzyme deficiencies are in agreement with experimental data and findings in literature.
Investigation of the dynamic properties of the fatty acid β-oxidation reveals that the formation of acetyl-CoA –
substrate for energy production – is highly impaired within the first hours of fasting corresponding to the rapid
progress to coma within 1–2 hours. LCAD deficiency exhibits the highest accumulation of fatty acids along with
marked increase of these substrates during catabolic stress and the lowest production rate of acetyl-CoA. These
findings might confirm gestational loss to be the explanation that no human cases of LCAD deficiency have been
described.
Conclusion: In summary, this work provides a detailed kinetic model of mitochondrial metabolism with specific
focus on fatty acid β-oxidation to simulate and predict the dynamic response of that metabolic network in the
context of human disease. Our findings offer insight into the disease process (e.g. rapid progress to coma) and
might confirm new explanations (no human cases of LCAD deficiency), which can hardly be obtained from
experimental data alone.
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Background
Mitochondrial β-oxidation of fatty acids plays a major
role in energy production, especially during periods of
fasting or low intensity exercise. The primary sources of
fatty acids for oxidation are dietary and mobilization of
triacylglycerols mainly stored in adipocytes of adipose tis-
sue. The release of metabolic energy, in the form of fatty
acids, is controlled by a complex series of interrelated cas-
cades that result in the activation of hormone-sensitive
lipase, which hydrolyzes fatty acids from triacylglycerols
and diacylglycerols. The final fatty acid is released from
monoacylglycerols through the action of monoacylglyc-
erol lipase, an enzyme active in the absence of hormonal
stimulation. Once released, these fatty acids travel
through the blood to other tissues such as muscle where
they are oxidized to provide energy through the mito-
chondrial β-oxidation pathway. The β-oxidation spiral of
fatty acid metabolism involves these four steps: oxidation,
hydration, a second oxidation, and finally thiolysis. These
occur in repeating cycles through the sequential removal
of 2 carbons and production of acetyl-CoA, which then
enters the Krebs cycle for oxidation and ATP production
(Figure 1). Another destination of acetyl-CoA is the pro-
duction of ketone bodies in the liver that are transported
to tissues like the heart and brain for energy production
during starvation. Fatty acids with an odd number of car-
bons in the acyl chain are left at the end with propionyl-
CoA, which is converted to succinyl-CoA that then also
enters the Krebs cycle. Furthermore, unsaturated fatty
acids with bonds in the cis configuration require three sep-
arate enzymatic steps to prepare themselves for the β-oxi-
dation pathway.
Mitochondrial fatty acid oxidation deficiencies are due to
genetic defects in enzymes of fatty acid β-oxidation and
transport proteins (clinically often summarized as
FATMO – fatty acid transport and mitochondrial oxida-
tion). Genetic defects have been identified in most of the
genes where nearly all types of sequence variations (muta-
tion types) have been associated with disease [1]. In par-
ticular, defects in fatty acid metabolism associated with
clinical disorders include defects in acyl-CoA dehydroge-
nase and β-hydroxyacyl-CoA dehydrogenase, which cata-
lyzes the first and third steps in β-oxidation, respectively.
Several acyl-CoA dehydrogenases were previously isolated
and described [2-6]. In general, these enzymes can be clas-
β-Oxidation pathway of fatty acids (with permission of Biocarta) Figure 1
β-Oxidation pathway of fatty acids (with permission of Biocarta). The β-oxidation cycle itself is catalyzed by a series 
of four enzymes in the mitochondrial matrix. Each turn of the cycle shortens the fatty acid chain by two carbon atoms and gen-
erates one molecule of acetyl CoA. We only consider even-chain saturated fatty acids.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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sified due to their fatty acid chain length specificity in
short-chain (SCAD), medium-chain (MCAD), long-chain
(LCAD), and very long-chain acyl-CoA dehydrogenases
(VLCAD). The enzymatic activity distributions of the fatty
acid chain length specificity of these four enzymes overlap
to some extent [2-4,7], as summarized in Figure 2A. Con-
sequently, the deficiency of one particular enzyme cannot
be compensated by the accumulated activity of the other
non-impaired enzymes (Figure 2B).
Ten of the disorders directly affecting mitochondrial fatty
acid oxidation have been well-defined, implicating epi-
sodic hypoketotic hypoglycemia provoked by catabolic
stress, multiple organ failure, muscle weakness, or hyper-
trophic cardiomyopathy. Additionally, syndromes of
severe maternal illness (HELLP syndrome and AFLP) have
been associated with pregnancies carrying a fetus affected
by fatty acid oxidation deficiencies. The incidence of one
of these disorders, MCAD deficiency (MIM 201450), is
1:14 600 in almost 8.2 million newborns worldwide [8].
In the first years of life this inherited deficiency may
become apparent following a prolonged fasting period,
sometimes in combination with infection or fever. An
acute attack usually features symptoms of lethargy, nausea
and vomiting, which rapidly progresses to coma within 1–
2 h. Up to 25% of MCAD patients die during their first
attack; or suffer permanent brain damage from cerebral
edema. The clinical phenotypes of most of the disorders
of fatty acid metabolism are very similar [9].
The introduction of tandem mass spectrometry (MS/MS)
for the analysis of plasma acylcarnitines has greatly facili-
tated the identification of patients with a defect in fatty
acid β-oxidation and has unquestionably been the most
striking recent advance in newborn screening. Pre-symp-
tomatic diagnosis is important to prevent morbidity as
most of the diagnosed defects are treatable and the prog-
nosis is generally favorable [10-12].
Besides statistical model building and data mining based
approaches [13-15], computational Systems Biology is
essential to combine knowledge of human physiology
and pathology starting from genomics, molecular biol-
ogy, and the environment through the levels of cells, tis-
sues, and organs all the way up to integrated systems
behavior. Applying Systems Biology approaches within
the context of human health and disease will definitely
gain new insights. Eventually, a new discipline – Systems
Medicine – will emerge at the interface between Medicine
and Systems Biology [16-18]. Higher levels of organiza-
tion are extremely complex and even models at the cell
and subcellular levels are forced to resort to simplifica-
tions to minimize modeling and computational complex-
ity [19-21]. Additionally, some parameters and constants
Specific enzyme complex activity of acyl-CoA dehydrogenase deficiencies Figure 2
Specific enzyme complex activity of acyl-CoA dehydrogenase deficiencies. (A) Activity distribution of four distinct 
acyl-CoA dehydrogenases with respect to fatty acid carbon chain length based on data from literature [3-5]. Short-chain 
(SCAD), medium-chain (MCAD), long-chain (LCAD) and very long-chain (VLCAD) acyl-CoA dehydrogenase is defined accord-
ing to the specific enzyme complex activity catalyzing dehydration of short-, medium-, long- and very long-chain fatty acids. The 
total activity of all four acyl-CoA dehydrogenases is shown in red (Total). (B) Total acyl-CoA dehydrogenase activity as a func-
tion of carbon chain length without deficiencies in enzyme activity (Control). Reduced activity of acyl-CoA dehydrogenases 
yields to different total activity reflecting deficiencies of short-chain (SCADD), medium-chain (MCADD), long-chain (LCADD) 
and very long-chain (VLCADD) acyl-CoA dehydrogenase, respectively.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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for kinetics, binding and concentrations of biomolecules
are typically not known, thus reducing the model's ability
to respond correctly to dynamic changes in external con-
ditions. A high-quality network of human-specific meta-
bolic pathways including detailed knowledge about all
metabolic reactions concerned is essential to design tai-
lored kinetic models for better understanding of human
metabolism and its relationship with diseases. While such
large networks are used to analyze the global structure or
functional connectivity of the network [22], deterministic
and stochastic models are mainly used for simulating spe-
cific metabolic pathways as well as regulatory and signal-
ing networks [23].
To date, little is known about fatty acids kinetics, espe-
cially during catabolic stress or exercise when the demand
for fatty acid oxidation is increased. Here we introduce a
detailed kinetic model of mitochondrial metabolism with
specific focus on fatty acid β-oxidation to simulate and
predict the dynamic response of that metabolic network
toward distinct enzyme deficiencies. The simulation
results are compared and validated using experimental
data. Finally, the dynamic response to changes in the
input to the system representing catabolic stress is simu-
lated and results are interpreted in a biological and clini-
cal context, followed by a discussion on limitations of the
model.
Results
Construction and evaluation of kinetic model
The major objectives of this study were to construct a
dynamic simulation environment allowing the explora-
tion of complex biochemical processes involved in fatty
acid β-oxidation, the validation of the model with experi-
mental data, and finally the application of these pathway
models to the analysis of metabolic diseases. We therefore
built a deterministic model describing the biochemical
reactions and pathway in the form of kinetic rate equa-
tions, and investigated the dynamic response of the sys-
tem to specific perturbations of enzyme activities. Based
on a publicly available computational model for mito-
chondrial metabolism (see the methods section) and pre-
viously described enzymatic activity distributions (Figure
2A, B), we were able to build a detailed kinetic model of
the mitochondrial β-oxidation, which allows to simulate
and analyze acyl-CoA dehydrogenase deficiencies. The
simulated concentrations of acyl-CoAs are shown in Fig-
ure 3. In healthy controls the maximum value was
observed for C16, followed by C14 reflecting the distribu-
tion of fatty acids entering the β-oxidation cycle with its
maximum at C16.
The reduced activity of acyl-CoA dehydrogenases leads to
a deviation of the total activity as compared to healthy
controls (Figure 2B) and, subsequently, to the accumula-
tion of specific acyl-CoAs (Figure 3). For example, the
reduced acyl-CoA dehydrogenase activity for fatty acids
with carbon chain lengths of 4 and 6 results mainly in an
increase of acyl-CoAs with carbon chain length 4 in case
of SCAD deficiency. The low enzyme activity in MCAD
deficiency at chain lengths of 6 to 12 is reflected by a high
concentration of octanoyl-CoA (C8). The model predicts
the accumulation of specific acyl-CoAs corresponding to
the investigated enzyme deficiencies which are in agree-
ment with findings in the literature [24].
Relationship between model and experimental data
Isotope-dilution MS/MS on plasma or whole blood facil-
itates the measurements of acylcarnitines and the diagno-
sis of newborns with a defect in fatty acid β-oxidation
[25,26]. The transport of fatty acyl-CoA into the mito-
chondria is accomplished via an acylcarnitine intermedi-
ate generated through trans-esterification of the fatty acid
moiety from CoA to carnitine by carnitine palmitoyl
transferase I (CPT I). The acylcarnitine molecules are then
transported across the organelle's inner membrane into
the mitochondrial matrix by carnitine acylcarnitine trans-
locase where the re-esterification of the fatty acyl-CoA
molecule and, eventually, β-oxidation occurs. The diagno-
sis of fatty acid β-oxidation disorders is based on the
assumption that there is an association between the accu-
mulations of specific chain length acylcarnitines in the
mitochondria with the deficiency of a distinct acyl-CoA
dehydrogenase in the mitochondrial matrix [27]. Amino
acid, carnitine and acylcarnitine concentrations were doc-
umented in newborn screening programs in Middle
Europe and South Australia [28,29]. A summary of
regional dissimilarities of acylcarnitines (with even-chain
saturated fatty acid acyl group) concentrations is provided
in Table 1.
In order to compare the data from the screening programs
to accumulating fatty acyl-CoA concentrations for the
simulated enzyme deficiencies, we calculated relative con-
centrations with respect to the simulated control group
(Controls) and healthy control from the screening pro-
grams, respectively. We did not directly compare acyl-CoA
in the mitochondria with measured acylcarnitine concen-
trations outside the mitochondria. Based on diagnostic
findings and conclusions in newborn screening programs
we assumed similar relative behavior of acylcarnitines and
acyl-CoAs. Simulation revealed that LCAD deficiency
showed the largest effect of acyl-CoA accumulation (179-
fold), followed by MCAD deficiency (53-fold) corre-
sponding well with experimentally derived MCAD defi-
ciency data (51-fold) of the Middle Europe data set
(Figure 4). A less strong effect (22-fold increase) was
observed on simulation data of SCAD deficiency. The
experimental and simulated VLCAD deficiency data differ
from each other. Simulations demonstrated an accumula-BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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tion of C14 and C16 as well as C18 to C22 while experi-
mental data indicated accumulation of C10 to C14 with
hardly any effect on C16 (experimental data of C20 and
C22 were not available).
We additionally provide acylcarnitine ratios with respect
to C4 concentration on experimentally derived data of
newborn screening programs in Middle Europe and South
Australia as well as simulation data with different C16
input (Simulation A and B, see the methods section) in
Table 2 and Table 3. The overall profile of the ratios
matches well, showing the highest ratio at C8/C4 for
MCAD deficiency (MCADD) and C14/C4 for VLCAD defi-
ciency (VLCADD).
Responses of the model to dynamic changes
Clinical manifestation of MCAD deficiency usually starts
after significant catabolic stress. When carbohydrate stores
are depleted, the organism switches to energy production
from stored triacylglycerols, which results in lipolysis and
release of fatty acids. In MCAD deficiency a dramatic rise
of plasma levels of specific free fatty acids is observable,
indicating impaired β-oxidation of respective chain-
length acyl-CoA. Additionally, ketones remain inappro-
priately low, reflecting the defect in hepatic fatty acid oxi-
dation. Hypoglycemia develops shortly thereafter,
probably because of excessive glucose utilization due to
the inability to switch to fat as a fuel [9]. Thus, we simu-
lated the consequences of the mobilization of fatty acids
induced by fasting leading to increased acyl-CoA concen-
trations for fatty acid β-oxidation by increasing palmitoyl-
Simulated acyl-CoA concentrations Figure 3
Simulated acyl-CoA concentrations. Simulated relative concentration of acyl-CoA as a function of carbon chain length for 
healthy controls (Control) and acyl-CoA dehydrogenase deficiencies (SCADD, MCADD, LCADD, VLCADD). The concentra-
tions of each deficiency are divided by the respective maximum value of concentration. The simulations show accumulation of 
acyl-CoAs with a maximum at carbon chain lengths of 4 (SCADD), 8 (MCADD), 14 (LCADD) and 16 (VLCAD, Control).BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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CoA (C16). An increase of about 20% showed more than
two-fold increases of octanoyl-CoA (C8) concentrations
for the deficiency MCAD and tetradecanoyl-CoA (C14)
for the deficiency LCAD, respectively (Figure 5). A lesser
effect was observed for the deficiencies SCAD and VLCAD.
A higher increase of palmitoyl-CoA (C16) resulted in
higher accumulation of specific acyl-CoA concentrations.
In Table 4 ratios of specific acyl-CoA concentrations
before and 30 days after 20%, 30%, and 40% increase of
palmitoyl-CoA (C16) are given.
Next we studied the repeating cycles of the β-oxidation
spiral of fatty acid metabolism that sequentially removes
2 carbons. After the palmitoyl-CoA (C16) concentration
was increased by about 20%, acyl-CoA concentrations
reached a steady-state after 6 hours in healthy controls
(Figure 6A). The depicted concentration values were
shifted in terms of their minima and normalized with
respect to their maximum change resulting in normalized
concentration values between 0 and 1. The increase of the
input to the β-oxidation cycle subsequently increased
acyl-CoAs along the cascade from C16 to C4 with a delay
of approximately one hour at a normalized concentration
of 0.5 (Figure 6B). In contrast, a similar increase needed
almost 10 days to attain equivalent steady-state in the
MCAD deficiency simulation (Figure 6C). Due to inade-
quate enzymatic activity, medium-chain acyl-CoAs accu-
mulate leading to a slow enzymatic clearance, specifically
of octanoyl-CoA (C8). While C16 to C10 were subse-
quently increased with delay twice as long as healthy con-
trols (Figure 6D), the subsequent increase of C8 to C4
switched resulting in a delay for C8 of 40 hours at a nor-
malized concentration of 0.5 (Figure 6C). The same char-
acteristic were found when increasing the palmitoyl-CoA
(C16) concentration by 30% and 40% (data not shown).
Acetyl-CoA – the final product of the β-oxidation spiral –
is required for the production of energy and ketone bod-
ies, especially during periods of fasting. Deficiencies of
acyl-CoA dehydrogenases resulted in reduced production
of acetyl-CoA. Following a 20% increase of palmitoyl-
CoA (C16) concentration, the highest shortage of 30 days
acetyl-CoA production was found in LCAD deficiency.
The acetyl-CoA generated by the β-oxidation within 30
days was reduced by 6.3% compared to acetyl-CoA gener-
ated in the healthy situation. Figure 7 depicts the relative
production rate of acetyl-CoA as a function of time fol-
lowing a 20% and 40% increase of C16. After 4 hours the
production rate of acetyl-CoA of healthy controls reached
its maximum. In the case of simulating MCAD deficiency,
the production rate of acetyl-CoA is still 50% below its
maximum after 4 hours; whereas simulations of the LCAD
deficiency showed a very low production rate of acetyl-
CoA even after 40 hours – reaching about 10% of the pro-
duction rate of healthy controls.
Discussion
The present computer simulation attempts to contribute
to a better understanding (explanation) of pathophysio-
logical aspects of a group of hereditary disorders impair-
ing mitochondrial β-oxidation. Several enzymes are
involved in mitochondrial fatty acid oxidation. For all of
Table 1: Acylcarnitine concentrations of screened newborns
Acylcarnitines [μmol/l] C4 C6 C8 C10 C12 C14 C16 C18
Middle Europe healthy controls (n = 590.216) median 0.38 0.12 0.10 0.09 0.13 0.21 4.37 0.97
IQR 0.27 0.14 0.07 0.09 0.09 0.13 2.18 0.52
MCAD deficiency (n = 63) median 0.40 1.31 5.14 0.59 0.11 0.19 3.47 0.80
IQR 0.23 1.27 8.78 0.64 0.10 0.12 1.59 0.46
VLCAD deficiency (n = 5) median 0.28 0.11 0.12 0.15 0.47 0.85 3.15 1.38
IQR 0.11 0.07 0.08 0.13 0.19 0.45 1.04 1.44
South Australia MCAD deficiency (n = 13) median 0.32 0.97 7.23 1.10 0.25 0.32 3.49 2.69
IQR 0.07 0.95 7.27 0.39 0.09 0.13 1.80 1.18
VLCAD deficiency (n = 3) median 0.40 0.16 0.15 0.34 1.19 2.41 4.99 3.11
IQR 0.27 0.08 0.10 0.21 0.42 2.71 3.22 5.43
Summary of regional dissimilarities of acylcarnitines (with even-chain saturated fatty acid acyl group) concentrations (median and interquartile range 
(IQR)) of newborns screened in Middle Europe and South Australia [28,29].BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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them, genetic defects impairing their function have been
described. The availability of modern analytical methods
has facilitated newborn screening for these disorders. For
the identification of patients with a defect in β-oxidation,
acylcarnitines in blood were evaluated showing a charac-
teristic profile depending on the affected enzyme even in
asymptomatic stage. We simulated the steady-state con-
centrations of acyl-CoAs in acyl-CoA dehydrogenase defi-
ciencies and compared the results to acylcarnitine data
from screening programs in Middle Europe and South
Australia. Results indicate that the overall characteristics
of the simulated accumulation of acyl-CoA show good
agreement with experimental data and findings in the lit-
erature (Figure 3 and Figure 4).
Differences in simulated C16 acyl-CoA and measured C16
acylcarnitine might be caused by the special biological
role of C16 acylcarnitine. From a biochemical perspective
it is not clearly evident why a decrease of acyl-CoA dehy-
drogenase activity (Figure 2B) would not impact the con-
centration of C16 acyl-CoA in the mitochondria, leading
to a much higher C16 acyl-CoA than C14 acyl-CoA con-
centration, which is reflected by the measured acylcarni-
tines (Table 1). It seems that there is an abundant pool of
C16 acylcarnitine in the blood, whose level is almost not
affected by mitochondrial fatty acid oxidation deficiencies
(as can be seen in Table 1). This might be reasonable,
since C16 acylcarnitine is an ester of an important satu-
rated fatty acid, which is involved in several biological
Simulated acyl-CoA concentrations and experimentally derived acylcarnitine data Figure 4
Simulated acyl-CoA concentrations and experimentally derived acylcarnitine data. Relative simulated concentra-
tion of acyl-CoA as a function of carbon chain length for healthy controls (Control) and acyl-CoA dehydrogenase deficiencies 
(SCADD, MCADD, LCADD, VLCADD). The concentrations are divided by the concentrations of the control group (Con-
trols). Additionally, experimentally derived acylcarnitine data for C4 to C18 of MCAD (expMCADD) and VLCAD (expVL-
CADD) deficiencies of the Middle Europe dataset are depicted. These data are divided by the concentrations of the 
corresponding experimental control data. Note that relative concentration values higher than 14 are shown on the top x-axis 
at carbon lengths of 4, 8 and 14. The experimental data are unlinked anonymous newborn screening data from Germany [28].BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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processes within the body – it is needed for energy, hor-
mone production, cellular membranes and for organ pad-
ding as well as for important signaling and stabilization
processes in the body.
Differences in simulated acyl-CoA ratios and measured
acylcarnitine ratios shown in Table 2 are mainly given by
the relatively small value of the simulated C4 acyl-CoA
concentration and the relatively large value of the C12
acyl-CoA concentration. Higher values for C4 and lower
values for C12 can be mainly generated by changing the
activity of the enzymes for chain length 4 and 12. The
problem is that we do not exactly know the total enzyme
activity because the enzyme activities are based on data
from rat liver mitochondria [3-5] (and not on data from
human mitochondria). Additionally, mitochondria from
different tissues can show different total acyl-CoA dehy-
drogenase activity as well as possible residual activities of
the deficient enzyme are also changing the total acyl-CoA
dehydrogenase activity of the individual patient. This
might be supported by the high inter-patient variance of
the measured acylcarnitines, which is caused not only by
the experimental error but also by the biological variance
between patients. For example, for some patient data the
C12 acylcarnitine concentration is higher than the C14
acylcarnitine concentration (data are not shown). The dis-
crepancy with C14 and C12 (for the simulation data the
C12 ratio is higher than the C14 ratio which was not
found in the experimental data) can be considered negli-
gible, because of the small difference between C14 and
C12 compared to the strong increase of C8 for MCADD.
The ratio C8/C14 is more than 10 fold higher than the
ratio C12/C14.
The clinical phenotypes of most of the disorders are very
similar. As MCAD deficiency is the most prevalent defect
among them we focused our discussion and biochemical
interpretation on this particular defect. Nevertheless, the
aspects are relevant to the pathogenesis of all fatty acid
oxidation defects. Patients with MCAD deficiency are
without clinical manifestations until a prolonged fasting
period sometimes in combination with infection or fever.
As a physiological response to this catabolic stress triacylg-
lycerols from adipose tissue are released and energy pro-
duction switches from carbohydrate to lipid utilization. In
healthy individuals, subsequently ketone body formation
by the liver is increased to provide this metabolic fuel for
brain and muscles.
The response to catabolic stress in patients with MCAD
deficiency shows a marked increase in plasma fatty acids,
mitochondrial acylcarnitines and acyl-CoAs. Severe symp-
toms of lethargy and nausea develop as a consequence of
encephalopathy, and patients can become dangerously ill,
sometimes before plasma glucose falls to hypoglycemic
levels. The progression to severe sickness proceeds within
a few hours. Patients often die in the course of the first epi-
sode or at least suffer from persistent brain damage. The
Table 2: MCADD ratios of model and experimentally derived data
MCADD C6/C4 C8/C4 C10/C4 C12/C4 C14/C4
Middle Europe 3.28 12.85 1.48 0.28 0.48
South Australia 3.03 22.59 3.44 0.78 1.00
Simulation A 9.22 47.97 5.68 4.28 3.67
Simulation B 9.82 90.55 5.97 4.43 3.78
C6/C4, C8/C4, C10/C4, C12/C4 and C14/C4 ratios for MCADD of acylcarnitine concentrations of experimentally derived data. Similar ratios of 
acyl-CoA concentrations are given for the simulation data.
Table 3: VLCADD ratios of model and experimentally derived data
VLCADD C6/C4 C8/C4 C10/C4 C12/C4 C14/C4
Middle Europe 0.39 0.43 0.54 1.68 3.04
South Australia 0.40 0.38 0.85 2.98 6.03
Simulation A 0.79 1.01 0.99 1.24 7.09
Simulation B 0.79 1.01 0.99 1.24 7.51
C6/C4, C8/C4, C10/C4, C12/C4 and C14/C4 ratios for VLCADD of acylcarnitine concentrations of experimentally derived data. Similar ratios of 
acyl-CoA concentrations are given for the simulation data.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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underlying pathogenetic mechanisms have been poorly
understood until now. To simulate the response to fasting
we assumed a 20% increase of palmitoyl CoA (C16) and
observed significant differences of the calculated meta-
bolic changes in acyl-CoA deficiencies with respect to the
healthy controls (Figure 5). One major consequence of
the disorder is inadequate ketone body formation to meet
tissue energy demands under conditions of fasting and
catabolic stress. Our calculations showed that formation
of acetyl-CoA – substrate for energy production via the tri-
carboxylic acid (TCA) cycle and ketogenesis – is impaired
(Figure 7). The simulation impressively showed the low
production rate of acetyl-CoA within the first hours,
which corresponds to the rapid disease progression after
onset. In addition, inadequate acetyl-CoA production has
secondary effects on flux through the TCA cycle, on regu-
lation of fatty acid oxidation, and on efficiency of gluco-
neogenesis, which contribute to pathogenesis [24].
The simulated accumulation of specific acyl-CoAs accord-
ing to the investigated enzyme deficiencies are in agree-
ment with the accumulation of plasma free fatty acid
intermediates, which enter the central nervous system and
exert toxic effects, which may explain the observed
encephalopathy and cerebral edema. In vitro experiments
on cerebral cortex of rats indicate that inhibition of energy
metabolism and oxidative stress induction by the accu-
mulating fatty acids may contribute to the pathophysiol-
ogy of encephalopathy [30,31].
Although several patients have been found to have
VLCAD deficiency, none have been documented with
LCAD deficiency [32]. This could arise from either gesta-
tional loss due to LCAD deficiency as seen in the mouse
model, a failure to recognize LCAD deficiency because the
phenotype differs so greatly from other inborn errors of
fatty acid metabolism, or absence of disease resulting
from LCAD deficiency in humans [33,34]. The dynamic
behavior of the simulation model of LCAD deficiency
exhibits the highest accumulation of fatty acids (179-fold
of C14 as can be seen in Figure 4) along with marked
increase of these substrates during fasting (Figure 5 and
Table 4) and the lowest production rate of acetyl-CoA
(Figure 7). These findings might confirm gestational loss
to be the explanation that no human cases of LCAD defi-
ciency have been described.
Our model can be extended to comprehensively test and
study deficiencies of mitochondrial trifunctional protein
and β-hydroxy-acyl-CoA dehydrogenase, or other diseases
of fatty acid oxidation such as carnitine cycle, electron
transfer and ketone synthesis defects. Furthermore, differ-
ences in the expression level of the enzymes in different
cells and tissues and their consequences on the dynamical
behavior of the β-oxidation can be investigated. Future
work will incorporate the enzymatic steps for unsaturated
fatty acids.
Conclusion
In summary, this work provides a stimulating example for
Systems Biology in the context of human disease revealing
insights into dynamic properties of complex biochemical
networks under the constraints of various disease condi-
tions. As analytical technologies for global and targeted
measurements mature, especially with regards to metabo-
lites, new findings and hypothesis can be verified utilizing
quantitative data. Furthermore, while mitochondrial defi-
ciencies are often treated with metabolites to stimulate the
enzyme activities, models will allow evaluation of the
influences of metabolite treatments at the mitochondrial
level, visualization of the dynamic behavior of the path-
way and exploration of a hypothetical rationale of the
treatment. In this respect, computational biology proves
to be able to uncover insights, which can hardly be
obtained from experimental data alone.
Methods
Model
The computational model for mitochondrial β-oxidation
was based on a publicly available E-Cell2 [35] simulation
model developed by Yugi and Tomita [21]. The latter is a
computational model of mitochondrial metabolism rep-
resentative of the entire organelle. We chose that model as
a starting point for building our own model as this model
is based on knowledge gathered from quantitative studies
of the organelle since the 1960s by dozen of researches. It
consists of 58 enzymatic reactions and 117 metabolites,
representing the respiratory chain, the TCA cycle, the fatty
acid β-oxidation and the inner-membrane transport sys-
tem. Previously published enzyme kinetics studies in the
literature were successfully integrated and packaged into a
Table 4: Ratios of simulated acyl-CoA concentrations before and 
after fasting
20% 30% 40%
Control C8-ratio 1.10 1.15 1.19
SCADD C4-ratio 1.28 1.44 1.62
MCADD C8-ratio 2.08 3.59 6.97
LCADD C14-ratio 2.29 2.89 3.46
VLCADD C14-ratio 1.16 1.25 1.33
Ratios of simulated acyl-CoA concentrations before and 30 days after 
20%, 30%, and 40% increase of palmitoyl-CoA (C16). Note that the 
time to attain the steady-state increases with higher increase of C16 
and is in case of LCADD higher than 30 days for 30% and 40% 
increase of C16 resulting in lower ratios (2.89 and 3.46) than the 
ratios calculated for MCADD (3.59 and 6.97).BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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single large model. All the enzymatic reactions are repre-
sented by rate equations found in literature. Of the total
of 471 kinetic parameters, 286 are quoted from articles,
whereas the rest of the parameters are computationally
estimated [21,36]. A supplementary document describing
that computational model can be found at http://www.e-
cell.org/ecell/about/supplements/
yugi_tomita_supplement.pdf/view. This work offered a
perfect starting point to construct a kinetic model for fatty
acid metabolism with particular focus on the β-oxidation
cycle and the objective to enhance our understanding of
various deficiencies of acyl-CoA dehydrogenases.
In order to strike a balance between simplicity and com-
plexity of our simulation model, we extracted the β-oxida-
tion part of the mitochondrial model (reducing
complexity), modified and completed it with respect to
simulating mitochondrial fatty acid oxidation deficien-
cies. The β-oxidation cycle together with the metabolite
transporting system originally comprised 8 different enzy-
matic reactions with 5 different reaction mechanisms. The
modifications of the original model comprise three cen-
tral parts that are essential for simulating mitochondrial
fatty acid oxidation deficiencies: (i) extension to the oxi-
dation of stearoyl-CoA (C18), arachidonoyl-CoA (C20)
and behenoyl-CoA (C22) (ii) input of short, medium and
long chain fatty acids entering the β-oxidation cycle (iii)
modeling of acyl-CoA dehydrogenase using four enzymes
classified by their fatty acid chain length specificity.
Ratios of simulated acyl-CoA concentrations before and after fasting Figure 5
Ratios of simulated acyl-CoA concentrations before and after fasting. Ratios of simulated acyl-CoA concentrations 
before and 30 days after a 20% increase of palmitoyl-CoA (C16). The dynamic change leads to more than two-fold increases of 
octanoyl-CoA (C8) concentrations for MCAD deficiency (MCADD) and tetradecanoyl-CoA (C14) for LCAD deficiency 
(LCADD), respectively.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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There is no evidence that the first three steps of the β-oxi-
dation cycle of stearoyl-CoA (C18), arachidonoyl-CoA
(C20) and behenoyl-CoA (C22) are different from the
steps of the other acyl-CoAs. We used the same parameters
for stearoyl-CoA (C18), arachidonoyl-CoA (C20) and
behenoyl-CoA (C22) as well as for the other acyl-CoAs,
and explored only the parameters of the oxoacyl-CoA thi-
olase – the fourth step of the β-oxidation cycle – in
dependence on the carbon chain length. However, simu-
lations revealed that the variation of these parameters
with regard to carbon chain length had no impact on acyl-
CoA concentrations (data are not shown). Therefore, we
set the parameters to the same values as for palmitoyl-CoA
(C16).
Short and medium chain fatty acids (C4 – C12) were
assumed to enter the β-oxidation cycle directly, whereas
long and very-long chain fatty acids (C14–C22) were
entering the cycle via the carnitine transporting system.
The input of short, medium and long chain fatty acids
entering the β-oxidation cycle depends on the concentra-
tion of the fatty acids in the inter-membrane space. A
higher input results in a higher output – the production of
acetyl-CoA – as can be seen in Figure 7. We modeled the
input as a source with constant levels of acyl CoAs enter-
ing the β-oxidation cycle and the output as a sink resulting
in a constant level of acetyl CoA. The distribution of the
fatty acids in the body depends on several conditions like
fatty acid transport conditions, metabolic conditions
Simulated dynamic acyl-CoA concentration during fasting Figure 6
Simulated dynamic acyl-CoA concentration during fasting. (A, B) Dynamic change of simulated concentrations of acyl-
CoA of different carbon chain length in healthy controls following a 20% increase of palmitoyl-CoA (C16) concentration. Con-
centration values were shifted in terms of their minima and normalized with respect to their maximum change resulting in nor-
malized concentration values between 0 and 1. After 4 hours almost all acyl-CoAs reached their new steady-state values. (C, 
D) A 20% increase needs much longer (10 days) to attain the steady-state in the MCAD deficiency simulation.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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(e.g., fasting or catabolic stress), ingestion, to name just a
few examples. Since we are interested in the accumulation
of acyl-CoAs and the formation of acetyl-CoA for various
deficiencies of acyl-CoA dehydrogenase and the corre-
sponding dynamic response to moderate increase of
palmitoyl-CoA (C16), we estimated the input of the beta-
oxidation with the objective to fit and reproduce the
experimentally derived acylcarnitine data of MCAD defi-
ciency.
The modeling of acyl-CoA dehydrogenase using four
enzymes classified by their fatty acid chain length specifi-
city is based on experimental findings shown by the distri-
bution of the enzyme activity in Figure 2.
We treated the mitochondrial matrix and intermembrane-
space free carnitines as well as the intermembrane-space
free CoA and acylCoA as fixed parameters in order to guar-
antee constant input of acylCoA to the beta-oxidation
cycle. We did not get any enlarged acylcarnitine pools in
all our calculations. If we set the mitochondrial matrix
and intermembrane-space free carnitines variable, very
small changes of mitochondrial matrix and intermem-
brane-space free carnitines were found resulting in a little
bit smaller flux of acylCoA entering the beta-oxidation
cycle. These very small changes did not impact on our
results (data not shown). The level of matrix CoA was set
high and variation of multiple magnitudes of that level
did not impact on our results (data not shown).
Simulated production of acetyl-CoA during fasting Figure 7
Simulated production of acetyl-CoA during fasting. Relative production rate of acetyl-CoA as a function of time follow-
ing a 20% and 40% increase of palmitoyl-CoA (C16) concentration. After 4 hours the production rate of acetyl-CoA of healthy 
controls reached its maximum. In the case of simulating MCAD deficiency, the production rate of acetyl-CoA is still 50% below 
its maximum after 4 hours; whereas simulations of the LCAD deficiency showed a very low production rate of acetyl-CoA 
even after 40 hours – reaching about 10% of the production rate of healthy controls.BMC Systems Biology 2009, 3:2 http://www.biomedcentral.com/1752-0509/3/2
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The final model consisted of 64 reactions with 91 com-
pounds (36 with fixed values) and 301 parameters. The
entire model at different simulation states in SBML format
can be found in the Additional files. The users can directly
open the SBML files in COPASI [37] or use other simula-
tion software http://sbml.org, and modify this model of β-
oxidation at different disease states.
Simulation
Starting with initial concentrations, steady-state values
were calculated under acyl-CoA dehydrogenase activity
conditions of healthy controls. Subsequently, that steady-
state of the model was the starting point to calculate
steady-state values under mitochondrial fatty acid oxida-
tion deficiencies conditions. These calculations are sum-
marized in simulation A. Results of simulation A were
compared and validated with experimental data. Finally,
the models obtained in simulation A were used in simula-
tion B where dynamic responses with respect to catabolic
stress were calculated.
The initial metabolite concentrations (see Additional file
1) are taken from the literature or set approximately to
their Km values of the enzymes [21]. Simulations are per-
formed by numerical integration of the rate equations
using the simulation software COPASI 4.2 Build 22 [37].
The acyl-CoA dehydrogenase activity was set according to
healthy controls shown in Figure 2B. The new steady-state
values of all metabolites were obtained by simulating the
concentrations over a one year period (see Additional file
2).
Simulation A
Starting from the steady-state values of healthy controls,
the acyl-CoA dehydrogenase activity was changed accord-
ing to Figure 2B. Again, the new steady-state values of all
metabolites for SCADD, MCADD, LCADD and VLCADD
were obtained by simulating the concentrations over a
one year period (see Additional files 3, 4, 5, 6). Results of
these simulations are shown in Figure 3 and 4.
Simulation B
In order to analyze the dynamic behavior of the model,
we increased palmitoyl-CoA (C16) in the inter-membrane
space by 20%, 30% and 40%. The dynamical behavior of
a 20% increase for the control group as well as for the dif-
ferent acyl-CoA dehydrogenase deficiencies are shown in
Figure 5, 6. In Table 4 ratios of specific acyl-CoA concen-
trations before and 30 days after 20%, 30%, and 40%
increase of palmitoyl-CoA (C16) are given. Finally,
dynamical behavior concerning acetyl-CoA production
simulating 20% as well as 40% increase of C16 is shown
in Figure 7. We have not found any direct physiological
evidence for our chosen 20% to 40% increase of palmi-
toyl-CoA with regards to catabolic stress. Our choice was
first based on an assumption that was subsequently sup-
ported by our analysis of the dynamical behavior of the β-
oxidation model. The performed simulations reveal that
higher increases of C16 do not change the characteristic of
the production rate of acetyl-CoA during the first few
hours. We are interested in exploring this time period in
particular, since rapid progress to coma of patients during
fasting occurs within 1–2 hours. Additionally a higher
increase of C16 results in higher accumulation of acyl-
CoAs as well as increases the time to attain the steady-state
of the system.
Validation and limitation
The three central modifications of the original model are
based on findings from literature or from performed sim-
ulations.
Overall validation was given by relating the calculated var-
iables of the model (the metabolites of the β-oxidation
cycle) to experimental available data from two new-born
screening programs in Europe and Australia (simulation
A). The overall characteristics of the simulated accumula-
tion of acyl-CoA show good agreement with experimental
data and findings in the literature (Figure 3 and Figure 4).
A limitation of our work relates to the direct comparison
of calculated and measured data. It has to be considered
that experimental data of the (isolated) mitochondria are
not available and that the available measured data are not
only influenced by the respective subsystem (the beta-oxi-
dation cycle), but also may reflect additional effects
caused by other subsystems and disease conditions.
Further limitations comprise that only saturated fatty
acids were considered and that the β-oxidation of unsatu-
rated fatty acids and odd-numbered chains of carbon were
not modeled. Furthermore, we did not include carbon
chain length dependencies of the activity of enoyl-CoA
hydratase,  β-hydroxyacyl-CoA dehydrogenase and 3-
ketoacyl-CoA thiolase.
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